These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27793035)

  • 1. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
    Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
    Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
    BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
    Fumagalli C; Rappa A; Casadio C; Betella I; Colombo N; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2020 Mar; 73(3):168-171. PubMed ID: 31537627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
    Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
    Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
    Endris V; Stenzinger A; Pfarr N; Penzel R; Möbs M; Lenze D; Darb-Esfahani S; Hummel M; Sabine-Merkelbach-Bruse ; Jung A; Lehmann U; Kreipe H; Kirchner T; Büttner R; Jochum W; Höfler G; Dietel M; Weichert W; Schirmacher P
    Virchows Arch; 2016 Jun; 468(6):697-705. PubMed ID: 27003155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    Vošmiková H; Ryška A; Sieglová K; Laco J
    Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
    Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
    Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
    Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 14. High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
    Mazzuccato G; De Bonis M; Carboni V; Marchetti C; Urbani A; Scambia G; Capoluongo E; Fagotti A; Minucci A
    Mol Biol Rep; 2020 Jun; 47(6):4897-4903. PubMed ID: 32468256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing.
    Ruiz A; Llort G; Yagüe C; Baena N; Viñas M; Torra M; Brunet A; Seguí MA; Saigí E; Guitart M
    Biomed Res Int; 2014; 2014():542541. PubMed ID: 25136594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
    Kwong A; Chen J; Shin VY; Ho JC; Law FB; Au CH; Chan TL; Ma ES; Ford JM
    Cancer Genet; 2015 Sep; 208(9):448-54. PubMed ID: 26271414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
    Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
    Gornjec A; Novakovic S; Stegel V; Hocevar M; Pohar Marinsek Z; Gazic B; Krajc M; Skof E
    BMC Cancer; 2019 Apr; 19(1):296. PubMed ID: 30940100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
    Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
    Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.